search
Back to results

Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU) (HIFU)

Primary Purpose

Breast Fibroadenoma

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Echopulse
Sponsored by
Theraclion
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breast Fibroadenoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Female patients 18 years or older with at least one diagnosed breast fibroadenoma.
  • Diagnosis of fibroadenoma must be based on:

    • clinical examination,
    • women ≤ 40 years of age: ultrasound image alone; women > 40 years of age: ultrasound image and mammogram,
    • histological confirmation of fibroadenoma of the breast.
  • Patient's fibroadenoma size as determined by ultrasound imaging: the longest diameter is limited to 25 mm.
  • Women of childbearing potential must have a negative urine pregnancy test within 72 hours prior to HIFU treatment.
  • Patient must be able to understand the nature and the extent of the study and the procédures required and be willing and able to complete the screening and study procedures.
  • Patient must give written informed consent (personally signed and dated) before completing any study-related procedure.

Exclusion Criteria:

  • Patient who is pregnant or breast-feeding.
  • Patient with history of ipsilateral breast cancer within 5 years prior to study inclusion or radio therapy to the target breast within 5 years prior to study inclusion.
  • Patient with implant on the treated breast.
  • Patient with target fibroadenoma pre-treated by cryoablation or interstitial laser therapy within 12 month before recruiting for HIFU.
  • Patient's fibroadenoma not clearly visible on the ultrasound images (in B mode) at the inclusion visit.
  • Patient participating in other studies using drugs or medical devices within 3 months prior to study inclusion or during study participation including the follow-up period.

Sites / Locations

  • Tubingen University Hospital

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Echopulse

Arm Description

Echopulse HIFU

Outcomes

Primary Outcome Measures

FA volume changes from baseline

Secondary Outcome Measures

Palpability
Lack of palpable lesion
Pain assessment
Pain free if pain at baseline (pain related to the FA)
Cosmetic result
Cosmetic result (as judged by investigator)
Gland vascularisation
Gland vascularisation (compared to baseline) power Doppler at day 7, month 6 and 12, year 2, 3, 4 and 5 after the HIFU session
Histological outcome
Histological outcome through core needle biopsy after 12 month
Energy settings
Energy setting to obtain reduction in volume or total regression of the FA at 12 months, 2, 3, 4 and 5 years follow-up
Breast immobilization
Quality and ease of use of breast immobilization
Duration of the treatment session
Duration of the treatment session (min)
Ease of implementation of treatment
Ease of implementation of treatment

Full Information

First Posted
December 10, 2013
Last Updated
May 25, 2018
Sponsor
Theraclion
search

1. Study Identification

Unique Protocol Identification Number
NCT02011919
Brief Title
Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)
Acronym
HIFU
Official Title
Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
December 2013 (undefined)
Primary Completion Date
January 2017 (Actual)
Study Completion Date
January 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Theraclion

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a monocenter, open-label, uncontrolled study in accordance with §23b MPG to evaluate the efficacy of the HIFU-treatment of fibroadenoma using the TH-One device Objectives Primary objective: To evaluate the efficacy of HIFU in the treatment of the breast fibroadenoma using the TH-One device Secondary objective: To evaluate the tolerability of the HIFU using the TH-One device

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Fibroadenoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
27 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Echopulse
Arm Type
Other
Arm Description
Echopulse HIFU
Intervention Type
Device
Intervention Name(s)
Echopulse
Intervention Description
HIFU Under ultrasound guidance
Primary Outcome Measure Information:
Title
FA volume changes from baseline
Time Frame
Every year during 5 years
Secondary Outcome Measure Information:
Title
Palpability
Description
Lack of palpable lesion
Time Frame
Every year during 5 years
Title
Pain assessment
Description
Pain free if pain at baseline (pain related to the FA)
Time Frame
Every year during 5 years
Title
Cosmetic result
Description
Cosmetic result (as judged by investigator)
Time Frame
Every year during 5 years
Title
Gland vascularisation
Description
Gland vascularisation (compared to baseline) power Doppler at day 7, month 6 and 12, year 2, 3, 4 and 5 after the HIFU session
Time Frame
Every year during 5 years
Title
Histological outcome
Description
Histological outcome through core needle biopsy after 12 month
Time Frame
Every year during 5 years
Title
Energy settings
Description
Energy setting to obtain reduction in volume or total regression of the FA at 12 months, 2, 3, 4 and 5 years follow-up
Time Frame
Every year during 5 years
Title
Breast immobilization
Description
Quality and ease of use of breast immobilization
Time Frame
Every year during 5 years
Title
Duration of the treatment session
Description
Duration of the treatment session (min)
Time Frame
Every year during 5 years
Title
Ease of implementation of treatment
Description
Ease of implementation of treatment
Time Frame
Every year during 5 years

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female patients 18 years or older with at least one diagnosed breast fibroadenoma. Diagnosis of fibroadenoma must be based on: clinical examination, women ≤ 40 years of age: ultrasound image alone; women > 40 years of age: ultrasound image and mammogram, histological confirmation of fibroadenoma of the breast. Patient's fibroadenoma size as determined by ultrasound imaging: the longest diameter is limited to 25 mm. Women of childbearing potential must have a negative urine pregnancy test within 72 hours prior to HIFU treatment. Patient must be able to understand the nature and the extent of the study and the procédures required and be willing and able to complete the screening and study procedures. Patient must give written informed consent (personally signed and dated) before completing any study-related procedure. Exclusion Criteria: Patient who is pregnant or breast-feeding. Patient with history of ipsilateral breast cancer within 5 years prior to study inclusion or radio therapy to the target breast within 5 years prior to study inclusion. Patient with implant on the treated breast. Patient with target fibroadenoma pre-treated by cryoablation or interstitial laser therapy within 12 month before recruiting for HIFU. Patient's fibroadenoma not clearly visible on the ultrasound images (in B mode) at the inclusion visit. Patient participating in other studies using drugs or medical devices within 3 months prior to study inclusion or during study participation including the follow-up period.
Facility Information:
Facility Name
Tubingen University Hospital
City
Tubingen
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
30204024
Citation
Hahn M, Fugunt R, Schoenfisch B, Oberlechner E, Gruber IV, Hoopmann U, Roehm C, Helms G, Taran FA, Hartkopf AD, Warzecha H, Wiesinger B, Brucker SY, Boeer B. High intensity focused ultrasound (HIFU) for the treatment of symptomatic breast fibroadenoma. Int J Hyperthermia. 2018;35(1):463-470. doi: 10.1080/02656736.2018.1508757. Epub 2018 Sep 11.
Results Reference
derived

Learn more about this trial

Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)

We'll reach out to this number within 24 hrs